[
  {
    "ts": null,
    "headline": "Zoetis to Participate in the 44th Annual J.P. Morgan Healthcare Conference",
    "summary": "PARSIPPANY, N.J., December 18, 2025--Zoetis Inc. (NYSE:ZTS) will participate in the 44th Annual J.P. Morgan Healthcare Conference on Monday, January 12, 2026. Kristin Peck, Chief Executive Officer, and Wetteny Joseph, Executive Vice President and Chief Financial Officer, will represent the company and respond to questions from analysts at 10:30 a.m. PT.",
    "url": "https://finnhub.io/api/news?id=e39ae537b6ad0ebcc654098bccb3bbdb29ecab94557a12b4b0e5bf2b74d1e6c4",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1766064600,
      "headline": "Zoetis to Participate in the 44th Annual J.P. Morgan Healthcare Conference",
      "id": 137821551,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ZTS",
      "source": "Yahoo",
      "summary": "PARSIPPANY, N.J., December 18, 2025--Zoetis Inc. (NYSE:ZTS) will participate in the 44th Annual J.P. Morgan Healthcare Conference on Monday, January 12, 2026. Kristin Peck, Chief Executive Officer, and Wetteny Joseph, Executive Vice President and Chief Financial Officer, will represent the company and respond to questions from analysts at 10:30 a.m. PT.",
      "url": "https://finnhub.io/api/news?id=e39ae537b6ad0ebcc654098bccb3bbdb29ecab94557a12b4b0e5bf2b74d1e6c4"
    }
  },
  {
    "ts": null,
    "headline": "Zoetis (ZTS) Valuation Check After $1.75 Billion Convertible Notes Deal and Dividend Hike",
    "summary": "Zoetis (ZTS) just wrapped up a $1.75 billion convertible senior notes deal, and that financing move is really the key to understanding where the stock could head next from here. See our latest analysis for Zoetis. Despite the flurry of news, including a 6% dividend hike and new pain therapy approvals, Zoetis shares now trade around $122.28, with a year to date share price return of roughly negative 25% and a one year total shareholder return also firmly negative. This suggests sentiment has...",
    "url": "https://finnhub.io/api/news?id=6d5c6f1cb69bb878bfbfd01a4582b60380ea9089446b3ec56aefa45697889d4b",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1766016953,
      "headline": "Zoetis (ZTS) Valuation Check After $1.75 Billion Convertible Notes Deal and Dividend Hike",
      "id": 137817620,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ZTS",
      "source": "Yahoo",
      "summary": "Zoetis (ZTS) just wrapped up a $1.75 billion convertible senior notes deal, and that financing move is really the key to understanding where the stock could head next from here. See our latest analysis for Zoetis. Despite the flurry of news, including a 6% dividend hike and new pain therapy approvals, Zoetis shares now trade around $122.28, with a year to date share price return of roughly negative 25% and a one year total shareholder return also firmly negative. This suggests sentiment has...",
      "url": "https://finnhub.io/api/news?id=6d5c6f1cb69bb878bfbfd01a4582b60380ea9089446b3ec56aefa45697889d4b"
    }
  }
]